No connection

Search Results

ATHE vs FORA

ATHE
Alterity Therapeutics Limited
BEARISH
Price
$3.55
Market Cap
$64.3M
Sector
Healthcare
AI Confidence
65%
FORA
Forian Inc.
BEARISH
Price
$2.14
Market Cap
$66.9M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ATHE
--
FORA
--
Forward P/E
ATHE
-4.49
FORA
23.78
P/B Ratio
ATHE
1038.03
FORA
2.23
P/S Ratio
ATHE
11.83
FORA
2.21
EV/EBITDA
ATHE
-2231.26
FORA
-9.93

Profitability

Gross Margin
ATHE
97.66%
FORA
53.21%
Operating Margin
ATHE
-185.73%
FORA
-24.44%
Profit Margin
ATHE
-223.35%
FORA
-9.5%
ROE
ATHE
-43.23%
FORA
-9.61%
ROA
ATHE
-28.09%
FORA
-5.15%

Growth

Revenue Growth
ATHE
80.9%
FORA
37.0%
Earnings Growth
ATHE
--
FORA
--

Financial Health

Debt/Equity
ATHE
0.0
FORA
0.0
Current Ratio
ATHE
12.98
FORA
2.96
Quick Ratio
ATHE
12.62
FORA
2.78

Dividends

Dividend Yield
ATHE
--
FORA
--
Payout Ratio
ATHE
0.0%
FORA
0.0%

AI Verdict

ATHE BEARISH

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score limits bankruptcy risk assessment. Despite strong revenue growth of 80.90% YoY and a pristine balance sheet with zero debt and a current ratio of 12.98, the company is deeply unprofitable with a profit margin of -223.35% and negative ROE of -43.23%. Valuation metrics are extreme, with a Price/Book of 1038.03 and a negative Forward P/E of -4.49, suggesting significant overvaluation relative to book and earnings. While insider sentiment is moderately positive at 40/100 and analysts project a high target price of $12.00, the lack of profitability, inconsistent cash flow data, and weak technical trend (0/100) raise serious concerns about sustainability.

Strengths
Exceptional revenue growth of 80.90% YoY, significantly above sector average of 23.74%
Zero debt with a Debt/Equity ratio of 0.00, indicating strong capital structure flexibility
Very high liquidity with Current Ratio of 12.98 and Quick Ratio of 12.62
Risks
Piotroski F-Score of 4/9 indicates weak financial health and limited profitability strength
Extremely high valuation: Price/Book of 1038.03 and negative Forward P/E suggest severe overvaluation
Deeply negative profitability: Profit margin of -223.35% and ROE of -43.23% signal ongoing losses
FORA BEARISH

FORA exhibits severe fundamental weakness as evidenced by a Piotroski F-Score of 2/9, indicating poor operational efficiency and financial health. While the company maintains a debt-free balance sheet and strong liquidity (Current Ratio 2.96), it is struggling to translate 37% revenue growth into bottom-line profitability. The technical trend is completely bearish (0/100) and the 5-year price performance is devastating (-82.8%), suggesting a long-term loss of investor confidence. Despite a healthy gross margin of 53.21%, the negative operating margins and lack of deterministic value markers make this a high-risk speculative play.

Strengths
Zero debt (Debt/Equity: 0.00)
Strong short-term liquidity (Current Ratio: 2.96)
Robust revenue growth (37% YoY)
Risks
Critically low Piotroski F-Score (2/9) indicating fundamental deterioration
Negative operating margins (-24.44%)
Severe long-term price depreciation (-82.8% over 5 years)

Compare Another Pair

ATHE vs FORA: Head-to-Head Comparison

This page compares Alterity Therapeutics Limited (ATHE) and Forian Inc. (FORA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile